Affordable Access

Access to the full text

Bioprosthetic tricuspid valve replacement in carcinoid heart disease from primary ovarian carcinoid tumor

Authors
  • Tsugu, Toshimitsu1, 2
  • Iwanaga, Shiro3
  • Murata, Mitsushige4
  • Fukuda, Keiichi1
  • 1 Keio University, Department of Cardiology, School of Medicine, Tokyo, Japan , Tokyo (Japan)
  • 2 Hino Municipal Hospital, Department of Cardiology, 4-3-1 Tamadaira, Hino, Tokyo, 191-0062, Japan , Tokyo (Japan)
  • 3 Saitama International Medical Center, Department of Cardiology, Saitama, Japan , Saitama (Japan)
  • 4 Keio University, Department of Laboratory Medicine, School of Medicine, Tokyo, Japan , Tokyo (Japan)
Type
Published Article
Journal
Journal of Medical Ultrasonics
Publisher
Springer Japan
Publication Date
Mar 12, 2015
Volume
42
Issue
3
Pages
401–403
Identifiers
DOI: 10.1007/s10396-015-0621-9
Source
Springer Nature
Keywords
License
Yellow

Abstract

Carcinoid heart disease (CHD) commonly occurs in association with primary gastrointestinal tract carcinoid tumors with hepatic metastases. Unlike primary gastrointestinal tract carcinoid tumors, primary ovarian carcinoid tumors may cause CHD without hepatic metastases, accounting for only 0.3 % of all carcinoid tumors. Only 37 cases of CHD from primary ovarian carcinoid tumors have been reported. We present a case of CHD in which tricuspid valve thickening and shortening led to reduced valve mobility with the resulting severe tricuspid regurgitation. Considering these characteristics of an abnormal tricuspid valve, we suspected CHD, but prosthetic valve replacement was performed without sufficient systemic examination before surgery. Two years after valve replacement, the patient underwent excision of a mass in the lower abdomen, which was diagnosed as an ovarian carcinoid tumor by histopathological examination. The patient has been observed for more than 3 years after tricuspid valve replacement. She has not experienced bioprosthetic valve leaflet degeneration or dysfunction, although it has been reported that bioprosthetic valves may degenerate in patients with carcinoid tumors. Sufficient systemic examinations should be performed to explore the cause of disease.

Report this publication

Statistics

Seen <100 times